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ABST RACT
SARS-COV 2 recently caused a global pandemic, with the first case
being reported in Romania in February 2020. Important restrictive
measures were imposed, so that the addressability of patients to medical
services decreased. Upper gastrointestinal bleeding had more severe
forms of evolution at the time of presentation, which required additional
methods of diagnosis and treatment. This is a retrospective study
performed on 268 patients, which aims to evaluate the type and
effectiveness of different treatment methods for upper gastrointestinal
bleeding during the COVID 19 pandemic. Severity assessment was
performed by measuring the Rockall score and additional methods of
diagnosis. The association of COVID-19 with upper gastrointestinal
bleeding can lead to much more severe outcomes for the patient, so
treatment must be sustained and fast established. If the initial therapeutic
methods fail, the other available therapeutic measures should be
introduced progressively and without delay to achieve the best possible
outcomes.

Introduction
Upper gastrointestinal bleeding is one of the most
frequent medical emergencies, which requires intensive
drug treatment or even surgery. It occurs more frequently
in the elderly, who often have associated comorbidities
such as cardiovascular, cerebrovascular, pulmonary or
renal diseases, which may be decompensated and thus
aggravated by untimely or intermittent bleeding [1]. The
location of the bleeding is proximal to the duodeno-jejunal
angle, the most important sources being represented by the
stomach, esophagus, even recent liver trauma or
instruments of the common bile duct, when hemobilia can
occur [2].
Due to different etiology, treatment and survival rates,
upper gastrointestinal bleeding has been divided into
bleeding due to variceal and non-varicose causes. Varicose
veins are the consequence of increased pressure in the
portal system, secondary to mechanical obstruction
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(destruction of liver architecture by fibrosis) and/or
dynamic obstruction (inability of hepatocytes to synthesize
nitric oxide) [3].
There are several locations where the porto-systemic
anastomosis can be present, the most important that can
cause bleeding being at the junction between the esophagus
and the stomach. The main factor that causes bleeding is
blood pressure in the vascular system, so above a pressure
of 10 mmHg in the portal system varices may be present,
and above 12 mmHg the risk of variceal rupture and
bleeding becomes significant [4].
Regarding the non-variceal etiology, the most
important cause is represented by peptic ulcer, which is at
the origin of 60-65% of all upper gastrointestinal bleeding
[5]. Generally, the main factor for the appearance of peptic
disease is the aggression of gastric acid on the protective
layer of the mucosa, followed by the erosion of the vessels
in the structure of the duodenal/gastric wall [6]. Over time,
acid aggression leads to the onset of esophagitis, gastritis
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and/or duodenitis, but which seem to have decreased in
frequency due to the introduction of proton pump inhibitors
and the eradication of helicobacter pylori through specific
antibiotic treatment in many of these patients [7].
Neoplastic pathology can appear both sporadically (in
people who have a diet rich in fats and smoked proteins,
who are smokers or in the presence of helicobacter pylori)
or in people with premalignant conditions (such as stomach
surgery) [8,9]. Genetic factors must also be taken into
consideration in families that develop a pattern of diffuse
pathology under the age of 40, the genes that predispose to
the appearance of neoplastic pathology leading to a
heterozygous germline mutation in CDH1 [10].
Other rare causes are represented by: gastric or
duodenal polyps, Dieulafoy and Mallory-Weis lesions,
aorto-duodenal fistulas secondary to an intense
atheromatous process at the level of the abdominal aorta,
and last but not least, hemobilia [6].
The clinical expression of upper gastrointestinal
hemorrhages
is
represented
by
hematemesis
(exteriorization of fresh blood through vomiting),
melanemesis (which is the result of the action of
hydrochloric acid on blood with a blackish appearance) and
melena (black, shiny, foul-smelling stool) [2].
When the volume of blood is considerable, it can
generate an accelerated transit (secondary to intestinal
irritation by the blood), the result being a particular clinical
expression of red or partially digested blood, eliminated
through the stool [11].
In addition to the common manifestations described,
upper gastrointestinal bleeding can be expressed by
syncope, decompensation of other cardiovascular events,
such as acute myocardial infarction or the sudden onset of
a stroke.
The gold standard for diagnosing upper gastrointestinal
bleeding is upper digestive endoscopy, which can specify
the location and severity of the lesion/risk of bleeding. In
addition, it can also have a therapeutic effect, leading to the
stopping of bleeding by performing minimally invasive
methods [12].
The Rockall risk scoring system was developed in
1996, based on several variables: patient age, blood
pressure, pulse, presence and severity of associated
comorbidities, endoscopic diagnosis (presence or absence
of hemorrhagic stigmata). This score is useful to determine
the evolution, risk of rebleeding and even death [13-15].
One of the most important factors that can stop upper
gastrointestinal bleeding is represented by the increase in
gastric and duodenal pH [16]. A pH value above 6
facilitates the aggregation of platelets and enables the
activation of the coagulation cascade, thus helping to stop
bleeding. This value must be maintained for 1-3 days to be
able to lead to stopping the bleeding [17]. Regarding the
healing of the ulcer that was the source of the bleeding, this

is achieved by maintaining the pH at values above 3 for
about 10 days [18]. This therapeutic goal can be achieved
by administering proton pump inhibitors or histamine H2
receptor inhibitors [19].
Other therapeutic methods are represented by
minimally invasive treatment, such as the use of the upper
gastrointestinal endoscope for perilesional injection of
procoagulant substances [20], as well as different types of
energy (mechanical, thermal) that can be used to eliminate
the vascular fistula [21]. Angioembolization is indicated if
endoscopic treatment fails, and when active bleeding
can be visualized or there are indirect signs of bleeding
such as: pseudoaneurysms, vascular spasm and focal
hypervascularity [22]. A variety of materials can be used
to induce thrombosis, from autologous blood clot to metal
coils and gelatin sponges [23]. If these treatment methods
also fail, the last therapeutic resource is represented by
surgical treatment, which consists of different procedures
(in situ hemostasis or various upper digestive resection
procedures) depending on the local lesion and the general
condition of the patient [24].
SARS-COV 2 is a betacoronavirus that recently caused
a global pandemic and was first identified in Wuhan,
China, in the bronchoalveolar lavage of patients with
severe pneumonia [25]. The first case of COVID 19
appeared in Romania on February 26, 2020, when
successive restrictive measures were imposed at the
national level. As a consequence, the addressability of
patients to medical services has decreased, thus presenting
late to medical institutions, that is with advanced/
complicated forms of the disease. In this context, upper
gastrointestinal bleeding took more severe forms of
evolution, not only due to late presentation but also due to
numerous other factors that had synergistic effects in some
patients.
Among these factors should be listed: the use of nonsteroidal/ steroidal anti-inflammatory drugs (used to
relieve fever or systemic inflammatory syndrome and to
stop the progression of fibrosis), the use of systemic
anticoagulants to prevent various forms of vascular
thrombosis, lifestyle changes (sedentary and fast food
consumption, increasing during the pandemic), as well
as long hospital stays in intensive care units where patients
are predisposed to developing severe forms of stress
ulcers [26].
The current study is a retrospective investigation that
aims to evaluate the type and effectiveness of different
treatment methods for upper gastrointestinal bleeding
(depending on their etiology and severity) during the
COVID 19 pandemic. For an objective evaluation, the
assessment of severity was achieved by measuring the
Rockall score, and identifying the best therapy according
to the risk class in which the patient was classified.
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Materials and Methods
In the present study, the cohort is represented by
patients who were admitted to the General Surgery
Department of the Pantelimon Emergency Hospital during
01.03.2020-31.03.2022, patients who presented for
hematemesis and/or melena as separate or combined
symptoms. Patients were identified based on clinical
procedure codes. Afterwards, they were classified by
performing upper gastrointestinal endoscopy, as an
objective diagnostic and possibly therapeutic method. In
the case of surgical interventions performed for resected
gastric tumors, only patients with hemorrhagic tumors
were enrolled in the study, as patients with neoplastic
stenosis met the exclusion criteria.
The criteria for inclusion in the study were represented
by: the presence of hematemesis, melanemesis and/or
melena at presentation, as well as the identification of the
source of hemorrhage by endoscopic methods or by direct
intraoperative visualization. The exclusion criteria are
represented by variceal etiology, portal hypertension, or
patients who did not agree to participate in the study. All
patients included in the study received consent forms to
participate in the study.

Results
Following the application of the inclusion and
exclusion criteria, 268 patients were enrolled in the study.
There were 59.3% men and 40.7% women, aged between
26 and 97 years (the average being 68.87), while 67.31%
of the patients came from an urban environment.
Regarding the etiology of upper digestive hemorrhages,
the most common cause was represented by peptic etiology
in 67.53% of cases. The presence of infection with the
SARS-COV 2 virus was identified in 8.95% of patients.
The Rockall score calculated for the patients enrolled
in the study had values between 0 and 10 (with an average
of 4.91), most of them having values close to 4 and
representing 17.2% of all patients.

Figure 1. Active bleeding distribution between stomach
and duodenum
In the case of peptic ulcer, active bleeding (during
endoscopic or intraoperative examination) was identified
in 13.81% of patients, with a comparable distribution
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between stomach and duodenum (49.18% vs 50.82%). The
rest of the patients were either with hemorrhagic stigmata
or without active bleeding at the time of examination
(Figure 1).
The presence of the SARS-COV 2 virus was identified
in 8 patients with duodenal ulcer and in 3 with gastric ulcer,
and active bleeding was found in 7 of these patients.
The Rockall score according to location was between
0-10 for the duodenum and 1-10 for the stomach; in both
subgroups, most patients were distributed around a score
of 6. In the case of active bleeding, above average results
were usually obtained.
Comorbidities associated with upper gastrointestinal
bleeding were represented by hypertension in 52.98% of
cases, followed by type II diabetes in 16.04% and
congestive heart failure in 11.94% of cases. In the peptic
etiology, other associated pathologies were also identified,
such as: acute pyelonephritis, hemorrhagic stroke in
patients admitted to intensive care, some of them with fatal
evolution.
Hemorrhagic gastric tumors represent 13.86% of all
cases of upper digestive hemorrhages, being more frequent
in men (25 out of 37 cases, with an average age of 67.97
years), of which those located at the antral level were
predominant (in 18 out of 37 cases) (Figure 2). In most
cases, the malignant pathology was associated with general
cardiovascular diseases (hypertension, ischemic coronary
disease, atrial fibrillation) but also rare diseases such as
Williams-Beuren syndrome (a 27-year-old patient with a
gastric tumor placed at the level of the fornix).

Figure 2. Placement of hemorrhagic gastric tumors
The association between 2 distinct neoplastic
pathologies was seen (in the form of synchronous cancer)
in 3 patients, 2 of whom had cephalic pancreatic cancer and
gastric cancer, and 1 patient had a gastric tumor associated
with a left adrenal gland cancer.
Regarding COVID 19, 8 patients presented with
hemorrhagic gastric tumors. The Rockall score of the
patients with malignant pathology was between 5 and 10,
the majority having a score of 9.
Other etiologies of upper gastrointestinal bleeding were
represented by hemorrhagic gastritis (10.07%), esophagitis
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(5.97%) and other rare causes including strangulated
transhiatal gastric hernia with active bleeding (2 cases), 2
cases of gastric polyps, 1 duodenal polyp, 1 case of
Mallory-Weiss syndrome and 1 case of duodenal
angiodysplasia.
Esophagitis occurred in equal proportion (8 cases) in
both men and women, most of them being overweight/
obese and with associated cardiovascular problems.
Hemorrhagic gastritis occurred especially in men in 16
out of 27 cases, most patients presenting a pathology with
comorbidities requiring chronic anticoagulant treatment.
Seven of 27 patients were on such therapy at the time of
evaluation for atrial fibrillation/recent acute myocardial
infarction or ischemic stroke, while 5 patients were
positive after PCR testing for SARS-COV 2. The Rockall
score of these patients was between 0 and 8, most having
values of 4.
The treatment administered to patients enrolled in the
study was represented by drug therapy (in 79.9% of cases),
treatment by minimally invasive methods (6.7% of
patients) and surgical treatment in patients who did not
respond to conservative treatment methods or minimally
invasive procedures (in 13.4% of cases).

Figure 3. The method of treatment established
Regarding peptic etiology, 96.79% of patients without
active bleeding were treated with proton pump inhibitors,
while 3.22% were treated by endoscopic methods. For
comparison, in the case of hemorrhagic peptic ulcer, 7
patients had an indication for surgical intervention, 12
patients needed minimally invasive intervention when
medical treatment failed and 6 patients only benefited from
proton pump inhibitors, treatment under which the
bleeding ceased.
The malignant pathology of the stomach was treated by
both surgical treatment and drug treatment to stop the
bleeding. For 27 out of 37 cases the surgical treatment was
used, and for the rest conservative treatment proved
effective.
For the other causes of upper digestive bleeding, drug
therapy was used in 48 of the 50 patients. One case was

treated by endoscopy (for duodenal polyp which was
removed) and another case was treated surgically for a
strangulated diaphragmatic hernia.

Figure 4. The Rockall Score

Discussion
Severe Acute Respiratory Syndrome Coronavirus 2
caused a global pandemic that had a huge impact on the
economy and the medical system, due to severe forms of
the disease and prolonged hospitalizations. The classic
symptomatology consists of the appearance of cough, fever,
myalgia, but also gastrointestinal symptoms such as:
diarrhea, vomiting and hematemesis or melena, symptoms
that are specific to bleeding from the digestive tract [27.28].
This variable symptomatology is due to the distribution
of ACE II receptors on the mucous membranes of the
respiratory and digestive tracts [29,30]. By binding the
viral S protein to this receptor, the integration of the virus
in the enterocyte/pneumocyte takes place [31,32]
Upper digestive hemorrhage externalized by melena or
hematemesis can occur in COVID 19 through a direct
mechanism, which is generated by the inflammatory
response caused by the integration of the virus into cells.
An indirect mechanism is also described, represented by
the ACE II receptor [33] which has a vasoconstrictive and
pro-inflammatory effect and which can lead to necrosis and
degeneration of the mucosa, thus causing ulceration and
bleeding [34].
As an infection that affects the respiratory tract in
patients who develop respiratory failure and hypoxemia,
mechanical ventilation is required. Associated with
ventilation, opioid and sedative medication is necessary,
which leads to a decrease in digestive motility and a
decrease in preload [35-37].
Regarding the therapeutic approach of patients with
COVID 19, it is complex and involves the administration
of several classes of drugs. Depending on the
symptoms/general condition, antiviral treatment with
Remdesivir, immunomodulatory treatment based on
corticosteroids or Tocilizumab (which inhibits the release
of cytokines with the triggering of the systemic
inflammatory response, but which can affect the mucous
membranes and cause bleeding) can be administered. In
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addition, nonsteroidal anti-inflammatory drugs can be
administered to lower body temperature and also for the
prophylaxis of deep vein thrombosis and pulmonary
thromboembolism [38].
Severe forms of COVID 19 can be associated with acute
respiratory distress syndrome (ARDS), with a massive and
uncontrollable release of cytokines such as IL-6, IL-8 and
TNF alpha, which can cause activation of the coagulation
cascade [39]. Other proinflammatory responses, such as
hyaline membrane formation in alveoli in the acute stage,
followed by interstitial widening and edema, and then
fibroblast proliferation in the organizing stage, are also
commonly encountered [40,41].
Dexamethasone is a synthetic corticoid that has antiinflammatory and immunosuppressive action. Its shortterm administration (3-5 days) can reduce the systemic
inflammatory response by decreasing the plasma
concentration of pro-inflammatory cytokines and thus
ameliorating the localized lung lesions associated with
COVID 19. All these therapeutic benefits are obtained at
the cost of decreasing the immunity mediated by T
lymphocytes and by decreasing the activity of
macrophages, being therefore recommended only in severe
cases due to the association of an increased risk of bacterial
infections [42]. Adverse effects of dexamethasone include
an increased occurrence of perforated or bleeding ulcers,
administration of the drug to intubated or hospitalized
patients may result in a 40% higher bleeding rate [43,44].
Another complication of severe disease COVID 19 is
the onset of sepsis (either of viral or bacterial origin) due
to prolonged mechanical ventilation. The consequence is
disseminated intravascular coagulation, initially causing
microthrombosis that can be located in the digestive
mucosa and have the appearance of ischemia. Due to the
consumption of coagulation factors, diffuse bleeding from
the tissues and mucous membranes may occur later [45].
Thus, infection with the SARS-COV 2 virus causes a
procoagulant status, which means that prevention of
thrombosis is mandatory. This can be achieved by
administering low molecular weight heparin (LMWH), or
with oral anticoagulants such as dicoumarins or new oral
anticoagulants (NOACs). Their risk of inducing gastrointestinal bleeding is much higher, while the administration
of prophylactic treatment with proton pump inhibitors does
not necessarily reduce the occurrence and recurrence of
upper gastrointestinal bleeding [46,47].
The general risk factors for the occurrence of
gastrointestinal bleeding in association with anticoagulant
treatment are advanced age, history of gastrointestinal
bleeding, association with antiplatelet treatment and
chronic kidney disease, factors that are relatively common
in patients with COVID 19 [48-50].
The therapeutic approach to upper gastrointestinal
bleeding includes treatment with proton pump inhibitors,
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endoscopic treatment and surgical therapy. With the
emergence of the infection with COVID 19 the number of
upper digestive endoscopies decreased (secondary to a
reduced presentation of patients in medical units), but
presenting a much more severe symptomatology. In
addition, the number of hemodynamically unstable patients
at presentation was higher than in the pre-pandemic period,
resulting in a lower success rate of conservative medical
therapy [26]. In the first 24 hours after presentation, it is
necessary to perform an upper digestive endoscopy; before
this is done, resuscitation and hemodynamic rebalancing of
the patients is carried out. Performing such an intervention
on a patient with COVID 19 can cause aerosols that can
infect the medical staff participating in performing it, and
can affect the lungs of ventilated patients [51,52].
Consequently, the European Society of Gastroenterology
maintains that endoscopy should only be performed when
absolutely necessary [53]. Cavaliere et al. proposed
endoscopy when the patient does not respond to
conservative treatment, as well as in cases of treatment
with proton pump inhibitors and blood transfusions [54].
An alternative to upper gastrointestinal endoscopy in
locating and evaluating bleeding is endocapsular
examination. This allows stratification of the risk of bleeding
and the need for interventional endoscopy or emergency
surgery, limiting the degree of exposure/contamination of
staff [55,56], and without a statistically significant
difference between diagnostic endoscopy and enterocapsule
in identifying the source of bleeding.
The advantages of the diagnostic enterocapsule are
represented by the lower risk of staff contamination (for
endoscopy it is necessary to have a gastroenterologist,
technician, anesthesiologist, nurse, etc.). In addition, it is
not necessary for the patient to be sedated/mechanically
ventilated, while the effectiveness of the two methods
seems to be comparable. The video capsule can be replaced
and cleaned quickly without the risk of contamination [57].
The main inconvenience of the enterocapsule is
represented by its degree of passivity, being only a
diagnostic element. Subsequent guidance of patients
requiring surgical or endoscopic intervention and adequate
peristalsis of the digestive tube are necessary to complete
the diagnosis [58,59]. Due to these shortcomings, the
number of endoscopies performed during the pandemic in
India has decreased. Most of the patients who were
admitted were diagnosed with either gastric ulcer or
duodenal peptic ulcer.
Interventional endoscopic treatment had a success rate
of 98.8%, with a rebleeding rate of 6.7% at 28 days, and
the infection rate of the patients combined with the staff
who performed the endoscopy did not exceed 1%. Thus,
although initially performed only in selected cases, the
endoscopic treatment seems to be effective and safe, the
rates of infection with COVID 19 being low [60].
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In the present study, the curative attitude had 3
components. Drug treatment represented by proton pump
inhibitors (Pantoprazole/ Omeprazole, 40mg), in
continuous infusion 200mg diluted in 50ml saline with an
administration rate of 2ml/hour. Endoscopic treatment,
with adrenaline injection diluted 1:10000 in serum,
electrocoagulation/ electroresection, application of
hemostatic clips or combinations of the above two
methods. Finally, the surgical treatment represented by
gastrotomy/pylorotomy with bleeding control or distal
resections with Billroth anastomosis was performed.
Regarding the malignant pathology, subtotal/total
resections were performed depending on the location of the
tumor, with the restoration of digestive continuity through
several types of anastomoses: Bilorth II, HofmeisterFinsterer, Roux-en-Y anastomosis, etc. [61,62]
For patients who had positive PCR tests for SARSCOV 2 infection and signs of upper gastrointestinal
bleeding, the treatment was represented by Remdesivir
200mg on the first day, then 100 mg/day for the next 7
days, Dexamethasone 8 mg 2 times a day in cases with
ARDS criteria and proton pump inhibitors in continuous
infusion. Administration of anticoagulant treatment was
initiated after 8 hours in cases where there were no signs of
active bleeding. If the hemoglobin value decreased by 2 g
in 24 hours without blood administration, or by 1 g after
the administration of more than one unit of blood,
therapeutic upper digestive endoscopy was performed. If
the COVID 19 test was positive and the patient
hemodynamically unstable secondary to bleeding, the
treatment was surgical, under antisecretory treatment in
continuous infusion, then antiviral treatment was
administered and after 8 hours anticoagulant therapy.
Following the statistical analysis, we found that
patients with Rockall scores of up to 6 points benefited
(regardless of etiology) from the administration of drug
treatment. At higher score values, surgical and endoscopic
treatment are required, so that the higher the Rockall score,
the higher the probability of a minimally invasive or
invasive treatment, with a strong statistical significance in
the study group (p<0.001).
Patients who presented with upper gastrointestinal
bleeding and specific symptoms of COVID 19 underwent
endoscopic and surgical treatment in a higher proportion
than the uninfected population for the same pathology,
their Rockall scores being 1 point higher than the standard
population. In 5 out of 24 cases the associated pathologies
generated hemodynamic instability at the time of
hospitalization in the general surgery department, requiring
emergency surgical intervention including tracheostomy
[63,64], and 3 out of 5 patients had a fatal outcome after
the first 24 hours.
The main limitation of the study was represented by the
fact that it was a retrospective investigation. Although the

conclusions reached are statistically relevant, how the
severity of upper gastrointestinal bleeding is influenced by
the presence or absence of SARS-COV 2 infection still
remains to be further investigated [65]. A possible
explanation could be represented by the prothrombotic and
ischemic state of the infection, which can affect the
protective barrier of the cavitary viscera with the
appearance of secondary ulcers.
Another explanation can be given by the effect of drugs
on the integrity of the stomach/duodenum. During the
pandemic, the consumption of medicinal substances
increased by the administration of non-steroidal antiinflammatory drugs used to treat cold symptoms, or by the
administration of other substances with the intention of
increasing the survival rate of patients. Colchicine was
used in the first months of the pandemic, a large dose of it
being known to produce gastritis and upper gastrointestinal
bleeding [66]. Tocilizumab has been introduced into
therapy to reduce the systemic inflammatory response by
inhibiting the action of IL-6, but has numerous side effects
such as bleeding, nausea, vomiting and ulceration [67].

Conclusions
In conclusion, the Rockall score used in the assessment
of the severity of gastrointestinal bleeding can predict quite
well the type of treatment required for each patient. The
association of COVID-19 with upper gastrointestinal
bleeding may lead to a poorer therapeutic outcome, so
treatment should be sustained. In case of initial therapeutic
failure, other available therapeutic measures should be
rapidly introduced to achieve the best possible outcome.
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